Advanced Oncology & Immunology Platforms for Accelerated Drug Discovery

Our Oncology & Immunology teams can support all of your research needs, ranging from target discovery to in vitro/in vivo pharmacology, translational research, and clinical biomarker testing to accelerate projects focused on cancer, autoimmune diseases, and rare genetic diseases (RGD).

We have established a disease model library comprised of over 2,000 animal models representing cancer, autoimmune diseases, and rare genetic diseases:

• Tumor model libraries of human cancer cell line-derived xenograft (CDX) models, patient-derived xenograft (PDX) models, drug-resistant models and metastasis models.
• Immuno-oncology libraries of murine syngeneic tumor models
• Sub-libraries of autoimmune and inflammation models
• Broad collection of RGD models

We have a world-class platform for in vitro and in vivo screens for target identification and validation, and we have also established a comprehensive Immuno-Oncology translational platform:

• Biomarker discovery platform with state of art technology including flow cytometry, NanoString, scRNAseq, RNAscope and multiplex IF;
• CAP certified lab for clinical pathology and flow cytometry with over 200 clinical validated biomarkers to support clinical drug development.
• Large animal (NHP, canine, swine) based translational research platform with state-of-art facility, comprehensive biomarker research and correlation capability

One-stop services platform for rare genetic diseases, from animal model creation to pre-clinical testing.

Rich experience in IND-enabling pharmacology studies for both FDA and NMPA filings, as either stand-alone or as integrated drug discovery programs.